ArticleHaematologica2021

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies.

Adam S Kittai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.